Enzalutamide
- Generic Name
- Enzalutamide
- Brand Names
- Xtandi, Enzalutamide Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16F4N4O2S
- CAS Number
- 915087-33-1
- Unique Ingredient Identifier
- 93T0T9GKNU
- Background
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieve...
- Indication
Enzalutamide is indicated for the treatment of castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (mCRPC). It is also used in combination with talazoparib for the treatment of adult patients with HRR gene-mutated mCRPC.
- Associated Conditions
- Castration Resistant Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 43
- Registration Number
- NCT05457257
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
- Conditions
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- James J. Peters Veterans Affairs Medical Center
- Target Recruit Count
- 200
- Registration Number
- NCT05422911
- Locations
- 🇺🇸
James J. Peters VA Medical Center, Bronx, New York, United States
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2022-08-16
- Target Recruit Count
- 900
- Registration Number
- NCT05406999
- Locations
- 🇨🇳
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, China
Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)
- Conditions
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 132
- Registration Number
- NCT05404139
- Locations
- 🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇨🇦Sunnybrook Research Institute, Toronto, Ontartio, Canada
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
- Conditions
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 168
- Registration Number
- NCT05393791
- Locations
- 🇦🇺
Eastern Health Box Hill, Box Hill, Victoria, Australia
🇦🇺Border Medical Oncology Research Unit / The Border Cancer Hospital, Albury, New South Wales, Australia
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT05367440
- Locations
- 🇬🇧
Research Site, Plymouth, United Kingdom
An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings
- Conditions
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 870
- Registration Number
- NCT05362149
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 657
- Registration Number
- NCT05252390
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸St. Vincent-Frontier Cancer Center, Billings, Montana, United States
🇺🇸Morristown Medical Center, Morristown, New Jersey, United States
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT05212857
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely
- Conditions
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 13779
- Registration Number
- NCT05202301
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.